Welcome to our dedicated page for Central Garden & Pet Co SEC filings (Ticker: CENTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the numbers behind Nylabone chew toys or Pennington grass seed? Most investors start by hunting through Central Garden & Pet’s dense SEC documents for a simple answer: how are the Pet and Garden segments really performing across seasons? Our platform brings those answers forward, whether you need the Central Garden & Pet insider trading Form 4 transactions or a quick view of working-capital trends buried deep in a 10-K.
Open any Central Garden & Pet quarterly earnings report 10-Q filing and you’ll see hundreds of pages of commodity-cost tables and acquisition footnotes. Stock Titan’s AI-powered summaries translate that complexity into plain English—highlighting cash-flow swings, raw-material exposure and margin shifts in seconds. Real-time alerts surface each Central Garden & Pet Form 4 insider transactions record the moment it hits EDGAR, while side-by-side tools compare last quarter’s disclosures with today’s update. It’s understanding Central Garden & Pet SEC documents with AI, not marathon reading sessions.
Need deeper detail? Drill into the Central Garden & Pet annual report 10-K simplified to track revenue by channel, scan the proxy statement executive compensation tables, or see how an 8-K material events explained notice affects guidance. Whether you’re monitoring Central Garden & Pet executive stock transactions Form 4 before busy planting season or seeking a concise Central Garden & Pet earnings report filing analysis, every form—from 10-Q to 8-K—appears here moments after filing, complete with expert context. Save hours, spot trends earlier, and make confident decisions with comprehensive, AI-enhanced coverage of all Central Garden & Pet SEC filings.
Central Garden & Pet Company (NASDAQ: CENT/CENTA) filed a Form 8-K on July 11, 2025 reporting that it has increased its financial outlook for the fiscal year ending September 28, 2025. The only substantive disclosure is contained in Item 2.02, which states that a press release with the updated guidance is attached as Exhibit 99.1. No specific revenue, EPS or margin targets are provided within the 8-K itself. Other sections are routine boilerplate, including exhibit lists, trading symbols and signatures.
The filing’s key takeaway for investors is the upward revision of fiscal-year guidance, indicating management’s confidence in current operating trends across its garden and pet segments. However, without numerical details, the magnitude of the improvement is unclear, and investors will need to review the referenced press release for precise figures.
TAO Synergies Inc. (formerly Synaptogenix, Inc.) has called a virtual special meeting of stockholders for August 6, 2025. Three proposals will be presented:
- Issuance Proposal (Proposal 1): Seek approval under Nasdaq Rules 5635(c) & 5635(d) to issue more than 20% of outstanding common shares in connection with a June 9, 2025 private placement and related warrants. The financing included (i) 5,500 shares of Series D Convertible Preferred Stock (stated value $1,000; 5% dividend; redeemable at 107%) initially convertible into 1,833,333 common shares at $3.00, (ii) five-year investor warrants for another 1,833,333 shares at $3.00 with full-ratchet anti-dilution, (iii) 1.2 million consultant warrants issued to James Altucher/Z-List Media at tiered exercise prices of $4–$12, and (iv) placement‐agent warrants for 55,000 shares at $3.00. Gross proceeds already received: $5.5 million; up to $14.9 million of additional cash could be raised if all warrants are exercised for cash.
- Plan Amendment Proposal (Proposal 2): Increase share authorization under the 2020 Equity Incentive Plan from 675,000 to 2,675,000 shares (+2 million) and rename it “TAO Synergies Inc. 2020 Equity Incentive Plan.” Remaining shares available before amendment are 123,286; management believes the increase will cover roughly two years of future equity awards.
- Adjournment Proposal (Proposal 3): Permit adjournment to solicit more proxies if necessary.
Dilution & Governance: Prior to the placement the Company had 1,756,682 common shares outstanding. Full conversion/exercise of the new securities would add up to 3,088,333 shares (plus anti-dilution adjustments), materially diluting existing holders. The Series D instrument carries a 5% dividend (15% upon triggering events) and voting rights based on as-converted shares, but holders may not vote on Proposal 1. The instruments prohibit variable-rate financings and give investors participation rights in future offerings until the preferred is redeemed.
Strategic Use of Proceeds: The Board intends to deploy up to $10 million to acquire Bittensor TAO tokens as part of a new cryptocurrency treasury strategy, in addition to general working capital.
Record Date & Quorum: Holders of common stock or Series C preferred at the close of business on June 9, 2025 (1,391,682 common shares outstanding; Series C voting power equivalent to 256,802 common shares) may vote. One-third of combined voting power constitutes a quorum.
Board Recommendation: FOR all proposals.
FAQ
What is the current stock price of Central Garden & Pet Co (CENTA)?
What is the market cap of Central Garden & Pet Co (CENTA)?
What are the core business segments of Central Garden & Pet Co.?
How does Central Garden & Pet Co. generate revenue?
What makes the company a significant player in its industry?
Can you explain the types of products offered in the pet segment?
What distinguishes the garden segment of the company?
How does Central Garden & Pet ensure product quality?
Which well-known brands are part of Central Garden & Pet's portfolio?
How does Central Garden & Pet Co. maintain its market relevance?
